论文部分内容阅读
初诊2型糖尿病患者70例随机分为磷酸西格列汀联合二甲双胍组(A组)35例,二甲双胍单药治疗组(B组)35例。测定治疗前及治疗24周后空腹血糖(FPG)、空腹胰岛素(FIns)、餐后2小时血糖(2h PG)、糖化血红蛋白(Hb A1C)及HOMA-IR等。结果:(1)治疗后两组受试者FPG、2h PG及Hb A1C均较治疗前下降(P<0.05),A组患者上述指标均低于B组(P<0.05);(2)治疗后两组受试者空腹胰岛素水平均有升高,HOMA-IR下降(P均<0.05),但A组治疗后空腹胰岛素水平高于B组(P<0.05)、治疗后两组间HOMA-IR无差异;(3)两组治疗后BMI及低血糖发生率无显著差异(P>0.05)。结论:对初诊2型糖尿病患者进行西格列汀联合二甲双胍治疗可有效控制血糖,且西格列汀可改善胰岛β细胞功能,低血糖发生风险低。
Seventy patients with newly diagnosed type 2 diabetes were randomly assigned to sitagliptin phosphate combined with metformin (group A) 35 and metformin monotherapy (group B) 35. Fasting blood glucose (FPG), fasting insulin (FIns), 2-hour postprandial glucose (2h PG), Hb A1C and HOMA-IR were measured before treatment and 24 weeks after treatment. Results: (1) The FPG, 2h PG and Hb A1C of the two groups after treatment were significantly lower than those before treatment (P <0.05). The above indexes in group A were lower than those in group B (P <0.05); (2) Fasting insulin levels and HOMA-IR decreased (P <0.05) in the latter two groups, but fasting insulin level in group A was higher than that in group B after treatment (P <0.05). After treatment, HOMA- IR no difference; (3) BMI and hypoglycemia incidence of two groups no significant difference (P> 0.05). Conclusions: Sitagliptin combined with metformin can effectively control blood glucose in newly diagnosed type 2 diabetic patients, and sitagliptin can improve pancreatic β-cell function with low risk of hypoglycemia.